

RESEARCH ARTICLE

Open Access

# Selection of peptides binding to metallic borides by screening M13 phage display libraries

Martin Ploss<sup>1</sup>, Sandra J Facey<sup>1</sup>, Carina Bruhn<sup>2</sup>, Limor Zemel<sup>3</sup>, Kathrin Hofmann<sup>2</sup>, Robert W Stark<sup>3</sup>, Barbara Albert<sup>2</sup> and Bernhard Hauer<sup>1\*</sup>

## Abstract

**Background:** Metal borides are a class of inorganic solids that is much less known and investigated than for example metal oxides or intermetallics. At the same time it is a highly versatile and interesting class of compounds in terms of physical and chemical properties, like semiconductivity, ferromagnetism, or catalytic activity. This makes these substances attractive for the generation of new materials. Very little is known about the interaction between organic materials and borides. To generate nanostructured and composite materials which consist of metal borides and organic modifiers it is necessary to develop new synthetic strategies. Phage peptide display libraries are commonly used to select peptides that bind specifically to metals, metal oxides, and semiconductors. Further, these binding peptides can serve as templates to control the nucleation and growth of inorganic nanoparticles. Additionally, the combination of two different binding motifs into a single bifunctional phage could be useful for the generation of new composite materials.

**Results:** In this study, we have identified a unique set of sequences that bind to amorphous and crystalline nickel boride (Ni<sub>3</sub>B) nanoparticles, from a random peptide library using the phage display technique. Using this technique, strong binders were identified that are selective for nickel boride. Sequence analysis of the peptides revealed that the sequences exhibit similar, yet subtle different patterns of amino acid usage. Although a predominant binding motif was not observed, certain charged amino acids emerged as essential in specific binding to both substrates. The 7-mer peptide sequence LGFREKE, isolated on amorphous Ni<sub>3</sub>B emerged as the best binder for both substrates. Fluorescence microscopy and atomic force microscopy confirmed the specific binding affinity of LGFREKE expressing phage to amorphous and crystalline Ni<sub>3</sub>B nanoparticles.

**Conclusions:** This study is, to our knowledge, the first to identify peptides that bind specifically to amorphous and to crystalline Ni<sub>3</sub>B nanoparticles. We think that the identified strong binding sequences described here could potentially serve for the utilisation of M13 phage as a viable alternative to other methods to create tailor-made boride composite materials or new catalytic surfaces by a biologically driven nano-assembly synthesis and structuring.

## Background

The diverse group of transition metal borides comprises compounds that exhibit or combine interesting physical properties such as semiconductivity, ferromagnetism, hardness, thermal and mechanical stability and oxidation resistance [1]. Some of the binary, ternary, and quaternary metal borides are even superconducting or represent some of the strongest permanent magnets [2,3]. Because of the high melting point of boron, the traditional

synthesis of metal borides does not result in nanoscale or nanostructured products. As an alternative, a room temperature synthesis of nickel boride nanoparticles via hydrolysis of NaBH<sub>4</sub> has been reported [4-7]. Biological systems, on the other hand, can synthesise materials under mild and environmentally benign conditions [8]. Nickel borides like Ni<sub>3</sub>B, Ni<sub>2</sub>B or NiB are considered to exhibit catalytic activity in all kinds of reduction reactions, and hydrogenation reactions [9-15]. Like iron borides they are expected to exhibit paramagnetism, ferro- or superparamagnetism [16,17]. The electrical conductivities of different nickel borides vary with their boron content. Thus, the nickel-boron system represents an interesting class of

\* Correspondence: [bernhard.hauer@itb.uni-stuttgart.de](mailto:bernhard.hauer@itb.uni-stuttgart.de)

<sup>1</sup>Institute of Technical Biochemistry, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany

Full list of author information is available at the end of the article

compounds for a model study on peptide-boride interactions and the potential of bio-modified inorganic solids. Until now nothing is known about the interaction between boron-containing materials and peptides, although peptides binding to solid surfaces have been extensively exploited for other chemical systems in nanoscale science because of their material selective properties [18-20]. To select for peptides that are capable of interacting with inorganic materials, phage peptide display is a powerful technique [21]. Phage display is a selection technique in which a combinatorial library of random peptides ( $\sim 10^9$ ) is expressed as a fusion with an M13 phage coat protein (usually p3), resulting in the display of the fused peptide on the surface of the phage particle. Selection of the desired peptides, which is usually a random 7- or 12-amino acid peptide, is achieved by multiple rounds of target binding, elution and amplification, a process known as biopanning (or panning). Because the DNA sequence for the displayed peptide is genetically fused to the p3 gene, the amino acid sequence of the phage-displayed peptide is readily obtained by sequencing the p3 encoding DNA.

Phage display has been used to identify peptides which specifically bind to metals like Ag, and Pd, and various inorganic materials like ZnO, SiO<sub>2</sub>, TiO<sub>2</sub>, ZnS, and CdS [22-29]. In the last few years, specific binding peptides to nickel have also been described [30-32]. Up to now, no specific binding peptides have been identified for borides in general, neither nanostructured nor bulk material, or more specifically nickel boride nanoparticles. The identification of such a selective binding peptide sequence would be a first, significant step towards peptide-modified boride materials and composites. Such linkers would help to make boride particles available for biological systems and allow for a tuning of the properties of borides using a biological peptide-enabled nano-assembly process.

Since to our knowledge no binding peptides to boride nanoparticles are described in the literature, our aim of this research was to identify peptides that bind specifically to metallic borides. This constitutes the first step in order to combine two different binding motifs e.g. a metallic and a ceramic boride into a single bifunctional phage or into a synthetic bifunctional peptide. This would be useful for the generation of new boride composite materials in which the physical properties of two different borides are unified which is until now not combinable. Peptides were selected after several rounds of screening with a commercial phage library. Several Ni<sub>3</sub>B-binding peptides were selected using nanoparticles of amorphous and crystalline Ni<sub>3</sub>B as targets. From the initial library, we identified ten phages that exhibit selective binding to either amorphous or crystalline or both using titer count analysis, fluorescence and atomic force microscopy.

## Results and discussion

### Isolation of Ni<sub>3</sub>B-binding peptides

To identify Ni<sub>3</sub>B-binding peptides, a commercial available M13 bacteriophage display library (Ph.D.-7; New England Biolabs) was screened against amorphous and crystalline Ni<sub>3</sub>B nanoparticles. In the Ph.D.-7 library, random linear heptapeptides are displayed as N-terminal fusions to the minor coat protein p3 of M13. The M13 phage p3 constructs used in the screening selection have five copies of the peptide displayed on the one end of the phage particle. Five rounds of biopanning were conducted for each of the amorphous and crystalline Ni<sub>3</sub>B substrates. Each biopanning round involved the steps of phage binding, removal of weak binding affinity phage by washing, and elution of bound phage by a rapid pH decrease. More stringent washing conditions were used in the additional rounds of panning. A 0.3% TBST wash solution was used to remove phage with low binding affinity to Ni<sub>3</sub>B during the second round, whereas 0.5%, 0.6%, and 0.8% TBST wash solutions were used for the third, fourth, and fifth round, respectively. A total of 58 phage clones were selected and analysed by DNA sequencing after the fourth and fifth round of biopanning against amorphous and crystalline Ni<sub>3</sub>B substrates. For amorphous Ni<sub>3</sub>B substrates, 30 peptides were identified coding for 15 different peptide sequences (designated with an A for amorphous). A summary of the peptides identified from biopanning against amorphous Ni<sub>3</sub>B is provided in Table 1. In the case of the biopanning against crystalline Ni<sub>3</sub>B substrates, 28 peptides were isolated coding for 28 different peptide sequences (designated with a C for crystalline) shown in Table 2. The fact that all the peptides which were identified for crystalline Ni<sub>3</sub>B are different, could be an indication of a more complex surface structure for crystalline Ni<sub>3</sub>B nanoparticles than for amorphous Ni<sub>3</sub>B nanoparticles. Interestingly, one peptide sequence, ANHQSAN, termed A6/C28, was isolated from both, amorphous and crystalline, Ni<sub>3</sub>B substrates. While most of the peptides, especially identified for the crystalline Ni<sub>3</sub>B substrate, were isolated only once, for the amorphous substrate the peptide A1 was isolated eight-times, A2 six-times, and A3 four-times, respectively.

### Characteristics of the identified binding peptides

Due to the fact that cysteines interfere with the p3-mediated M13 infection process, no cysteines were present in the identified binding peptides [33]. The binding peptides showed approximately three-times more positively charged residues (K, R, and H) than negatively charged residues (D and E) (Table 3). Compared with the peptides binding to amorphous Ni<sub>3</sub>B, the binding peptides to crystalline nickel boride show a two-times higher occurrence of the positively charged amino acids arginine and lysine, and a three-times higher occurrence

**Table 1 Summary of the isolated binding peptides to amorphous Ni<sub>3</sub>B**

Peptide	Frequency	Sequence	Number of functional amino acid residues			pI
			Basic	Acidic	Hydrophobic	
A4	1/30	SEIVDNH	1	2	2	4.35
A1	8/30	TNLTLAS	0	0	3	5.19
A2	6/30	GALPNNL	0	0	3	5.52
A8	1/30	NVNSTSF	0	0	2	5.52
A9	1/30	SPDTVQK	1	1	1	5.55
A10	1/30	GNRLSAD	1	1	2	5.84
A7	1/30	LGFREKE	2	2	2	6.14
A11	1/30	TQVYHPM	1	0	3	6.40
A6	1/30	ANHQSAN	1	0	2	6.19
A5	1/30	TNSSFHK	2	0	1	8.44
A12	1/30	NTVIYQK	1	0	3	8.59
A13	1/30	HVQYWQF	2	0	3	8.75
A3	4/30	SLAVSRS	1	0	3	9.47
A14	1/30	VSVNSRT	1	0	2	9.72
A15	1/30	RLLNPWI	1	0	4	9.75

of histidine, respectively. Although the distribution of charged amino acids in the library is comparable in frequency, the increased abundance of these amino acids within the identified sequences could be possibly attributed to the surface composition of the nickel borides. The characterisation of the surface of different amorphous nickel borides by Okamoto *et al.* and Caputo *et al.* by X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD), respectively, revealed that the electron densities on nickel are increased by electron transfer from boron to the metal [6,34]. Based on the shift of the charge, specific binding peptides could therefore interact with the nickel boride substrates via electrostatic interactions. The majority of the peptides identified on Ni<sub>3</sub>B prevalently possess alanine, leucine, proline, serine and threonine residues (Figure 1) which is a consequence of the amino acid distribution of the applied phage display library. In addition, the binding peptides identified on amorphous Ni<sub>3</sub>B possess 2.5-times more asparagine residues as compared with the peptides identified on crystalline Ni<sub>3</sub>B. This is vice versa with proline residues binding to crystalline Ni<sub>3</sub>B. The strong presence of asparagine in the peptide sequences binding to amorphous Ni<sub>3</sub>B, and asparagine and histidine in the peptide sequences binding to crystalline Ni<sub>3</sub>B suggests that the binding between the Ni<sub>3</sub>B and peptides could furthermore occur via hydrogen bonding interactions. The almost complete absence of tryptophan, phenylalanine, and methionine residues is also due to the low frequencies of these amino acids within the library. An amino acid position consensus was not evident from the 7-mer library screening of Ni<sub>3</sub>B nanoparticles as substrates.

However, besides the predominantly hydrophobic amino acids (A and L) and hydrophilic amino acids (S and T) the variety of amino acids with charged side groups implies that these groups could be essential in specific binding to both substrates via electrostatic interactions. The Ni<sub>3</sub>B-binding peptides identified possess calculated theoretical isoelectric points (pI) ranging from strongly acidic (4.0) to highly basic (9.75). 60% of the peptides binding to amorphous Ni<sub>3</sub>B show a pI value < 7.5 while 40% of the peptides have pI > 7.5. 57% of the peptides binding to crystalline Ni<sub>3</sub>B show a pI value < 7.5 and 43% of the peptides have pI > 7.5. Therefore the identified peptides can be grouped into the categories acidic (pI 3.0 - 5.9; 35.7% of the peptides), neutral (pI 6.0 - 8.9; 52.4% of the peptides), and basic (pI 9.0 - 12; 11.9% of the peptides), respectively.

#### Relative binding affinity experiments

Because of the heterogeneity of all of the identified binding peptides and the absence of a distinctive binding motif, the binding strength of each of the 42 identified peptides to amorphous (Figure 2A) and crystalline (Figure 2B) Ni<sub>3</sub>B was determined by titer assays. Since previously binding affinity experiments at pH 5 or pH 9 with a subset of the identified binding peptides showed no increase in binding affinity (data not shown) the relative binding affinity experiments were carried out at pH 7. As a control to verify that the peptide was the interactor of interest, M13KE wild-type (M13wt) phage without a random peptide insert were compared in the same manner as the peptide clones. As presented in Figure 2A, most of the phage clones, except C2 and C17, bind to amorphous Ni<sub>3</sub>B with greater affinity than

**Table 2 Summary of the isolated binding peptides to crystalline Ni<sub>3</sub>B**

Peptide	Frequency	Sequence	Number of functional amino acid residues			pI
			Basic	Acidic	Hydrophobic	
C15	1/28	LEQTPMF	0	1	3	4.00
C16	1/28	ELTQISS	0	1	2	4.00
C2	1/28	SDPQHTT	1	1	0	5.06
C3	1/28	TPPLLSP	0	0	2	5.19
C17	1/28	MNHAESY	1	1	2	5.22
C18	1/28	VPSLTPT	0	0	2	5.49
C4	1/28	VPIPYLP	0	0	4	5.49
C19	1/28	DPYNRIN	1	1	2	5.84
C20	1/28	RTFDAIS	1	1	3	5.84
C21	1/28	YELVLPK	1	1	4	6.00
C5	1/28	ETFPARG	1	1	2	6.10
C13	1/28	GPVNHQL	1	0	2	6.74
C22	1/28	LNHVLP	1	0	4	6.74
C23	1/28	HAMRTEP	2	1	2	6.75
C6	1/28	ATSTAHA	1	0	3	6.79
C28	1/28	ANHQSAN	1	0	2	6.79
C10	1/28	SYTKLIIL	2	0	3	8.33
C1	1/28	SPPKSNA	1	0	1	8.47
C9	1/28	SASKVHN	2	0	2	8.49
C24	1/28	SPSTHWK	2	0	1	8.49
C25	1/28	WNAKYTL	1	0	4	8.59
C12	1/28	YQVVPAR	1	0	4	8.75
C26	1/28	GDPKAAR	2	1	2	8.75
C11	1/28	GDHSRHK	4	1	0	8.76
C14	1/28	AGLPKHQ	2	0	2	8.80
C27	1/28	STFNSRV	1	0	2	9.47
C8	1/28	VHTNPSR	2	0	1	9.73
C7	1/28	GASATRT	1	0	2	9.75

does the M13wt phage, which shows a binding affinity of  $2 \times 10^7$  pfu/ml with amorphous Ni<sub>3</sub>B. Compared with the M13wt phage, 9 out of 42 identified peptides (see arrows in Figure 2A) bound on average 100-times and 28 on average ten-times more efficiently to amorphous Ni<sub>3</sub>B than the wild-type, verifying that binding to the substrate was a result of the peptide sequence and not due to non-specific phage coat protein interactions. The peptides A7, C12, and C15 (see arrows in Figure 2B) bound on average 1000-times more efficiently to crystalline Ni<sub>3</sub>B as compared to the M13wt phage, which shows a binding affinity of  $5 \times 10^6$  pfu/ml. Interestingly, the phage clone A7 identified for amorphous Ni<sub>3</sub>B shows a higher binding affinity to crystalline Ni<sub>3</sub>B than most of the Ni<sub>3</sub>B-binding peptides (C1-C11, C13-C14, and C16-C28) identified for crystalline Ni<sub>3</sub>B. In addition, the amorphous Ni<sub>3</sub>B-binding peptides A8-A10 show a

higher binding affinity to crystalline Ni<sub>3</sub>B ( $\geq 10^9$  pfu/ml) than several binding peptides found for crystalline Ni<sub>3</sub>B specifically (i.e. C1-C11, C13-C14, C16-C24, and C27-28). The relative binding affinity experiments revealed a set of several strong binders ( $>10^9$  pfu/ml) for amorphous (A1-A3, A7, C4, C9, C13, C15, and C24) and crystalline (A7, C12, and C15) substrates (Table 4). The phages displaying the peptides A7 and C15 emerged as the best binders for both substrates.

#### Competitive binding assays of the best binding peptides

The competitive binding assay represents a method to determine the most selective binding peptide sequence from a large subset of phage display results [35]. To identify a specifically recognised structural correlation between the surfaces of amorphous and crystalline Ni<sub>3</sub>B nanoparticles, the individual phage clones of the nine

**Table 3 Occurrences of amino acids of the isolated Ni<sub>3</sub>B binding peptides**

Amino acid	Averaged quantity of occurrences per heptapeptide	
	Amorphous	Crystalline
A	0.70	0.68
R	0.20	0.36
N	1.00	0.43
D	0.10	0.18
C	<b>0.00</b>	<b>0.00</b>
Q	0.20	0.25
E	0.10	0.21
G	0.27	0.21
H	0.17	0.50
I	0.10	0.14
L	1.20	0.50
K	0.13	0.29
M	0.03	0.11
F	0.10	0.14
P	0.30	0.82
S	1.00	0.75
T	0.73	0.68
W	0.07	0.07
Y	0.10	0.25
V	0.40	0.36

strongest binders (A1-A3, A7, C4, C9, C13, C15, and C24) to amorphous Ni<sub>3</sub>B as determined by the relative binding affinity experiments were diluted into a single mini-phage library. The mini-phage library was then screened against amorphous or crystalline Ni<sub>3</sub>B substrates. To receive better statistical results, the competitive binding assays were repeated three-times. After a single panning experiment, the strongly bound phages were isolated and a total of 58 phage clones were randomly selected and analysed by DNA sequencing to identify the strongest binding peptides. In Tables 5 and 6 the most abundant sequence indicates the strongest binding peptide to amorphous and crystalline Ni<sub>3</sub>B, respectively. Among the 58 randomly chosen plaques, the phage displaying the A7 peptide LGFREKE has the strongest binding affinity to amorphous (seventeen-times, ~58%) and crystalline (thirteen-times, ~45%) Ni<sub>3</sub>B. Interestingly, the amino acids lysine, arginine, and glutamic acid were shown to have a pronounced adhesion of their charged side groups to amorphous Si<sub>3</sub>N<sub>4</sub> and SiO<sub>2</sub> under aqueous conditions [36]. It was also reported, that the surface of amorphous Si<sub>3</sub>N<sub>4</sub> may present negative sites in solution [37]. Therefore substrates, possessing negatively surface charges in aqueous solution with pH values less than the intrinsic pK<sub>a</sub> of the side


chain of a basic amino acid, a peptide containing basic amino acids will be positively charged at these groups and will provide an attractive interaction to the given surface [36]. In aqueous solutions with higher pH values than the intrinsic pK<sub>a</sub> of the side chain of an acidic amino acid, a peptide containing acidic amino acids will be negatively charged at these groups. Based on these facts, the best binder A7 (LGFREKE) possesses in solution at pH 7 an alternating series of positively and negatively charged side chains in its peptide sequence which could be responsible for an interaction between the charge depleted boron and the electrons accumulated on the nickel side of amorphous and crystalline Ni<sub>3</sub>B nanoparticles. In contrast, the 7-mer peptide sequence TNLTLAS, termed A1, which emerged as the dominant amorphous Ni<sub>3</sub>B binder in the initial screening, possesses no charged side chain. The lack of electrostatic interactions might contribute to the observed fact, that it does not show the highest frequency in the competitive assay.

#### Fluorescence microscopy of Ni<sub>3</sub>B-M13 complex

The binding of phage displaying the A7 peptide LGFREKE to amorphous and crystalline Ni<sub>3</sub>B nanoparticles was confirmed by fluorescence microscopy. Amplified phage displaying the LGFREKE peptide were incubated either with amorphous or crystalline Ni<sub>3</sub>B nanoparticles and then washed to remove the nonspecifically bound phage particles. The samples were then dyed using a fluorescently tagged anti-M13 monoclonal antibody and washed again to eliminate nonspecifically bound anti-M13 antibodies. The fluorescence confocal images in Figure 3A and C show the LGFREKE displaying phage binding to the surface of amorphous and crystalline Ni<sub>3</sub>B nanoparticles, respectively. Considerable fluorescence emits from the surfaces of the LGFREKE phage-Ni<sub>3</sub>B nanoparticles. Although the relative binding affinity experiments showed an unspecific binding of the wild-type phage to the Ni<sub>3</sub>B substrates, the control experiments (Figure 3E and G) showed no fluorescence. This could be due to the fact that the concentration of bound phage is below the detection limit.

#### AFM measurements

To verify the interaction between M13 phage displaying the A7 peptide on the p3 coat protein and Ni<sub>3</sub>B particles, AFM measurements of phage bound to amorphous and crystalline Ni<sub>3</sub>B particles were carried out (Figure 4). The modified M13 phage were incubated either with amorphous or crystalline nanoparticles as shown in Figure 4A and B, respectively. As shown in Figure 4A and B the height of the colour scale exceeds the height of the particles. This colour scale was chosen to show the 100-nm-thick particles together with the 6-nm-thick phage. Individual phage




**Figure 1** Amino acid distribution of the isolated peptide sequences. A total of 15 peptide sequences were analysed for amorphous Ni<sub>3</sub>B (grey bars) and a total of 28 peptide sequences were analysed for crystalline Ni<sub>3</sub>B (black bars).

are approximately 1  $\mu\text{m}$  in length and 6.5 nm in height. This cross section and length of the modified phage correspond to that of M13 wt phage (data not shown). Some phage were oriented with their ends towards a nanoparticle (see arrows in Figure 4), which implies an affinity between the modified phage proteins and the particle. There are a few particles that seem to be attached to the unmodified side of the phage. Possible explanations for this observation include unspecific interaction or the presence of more than one phage, i.e. bundles of phage where the end of one phage coincides with the side of another phage. A small level of unspecific interaction between nanoparticles and phage cannot be avoided during preparation for AFM imaging. The phage oriented with their ends towards the nanoparticles, suggest that the peptide LGFREKE interacts with both amorphous and crystalline Ni<sub>3</sub>B nanoparticles.

## Conclusions

Metal borides are inorganic solids that are very interesting due to their high versatility in physical properties, as for example magnetism, electrical and thermal conductivity, hardness and catalytic activity, but at the same time they are difficult to prepare. Besides the application as catalysts in all kinds of reduction reactions, and hydrogenation reactions, metallic borides are employed for the generation of conductive ceramics, hard magnets, superconductors, and hard materials [9-15,38-40]. Typical synthesis routes employ high reaction temperatures and do not allow for a directed synthesis of particles that are well-defined in terms of size, shape, uniformity, phase purity, or crystallinity.

Formation of metal boride nanoparticles in solvents has been described occasionally, but an interaction of borides with biological material or bio-molecules like peptides was unknown before [4,5]. To the best of our knowledge, the present study is the first to identify peptides that bind specifically to amorphous and to crystalline Ni<sub>3</sub>B nanoparticles. Although all identified peptide sequences showed no significant binding motif, the analysis of the resulting Ni<sub>3</sub>B-binding sequences found them to be enriched in charged amino acids. The identified binding sequences possessed approximately three times more positively charged than negatively charged amino acids which leads to the assumption of electrostatic interactions between the identified binding peptides and the Ni<sub>3</sub>B substrates. Fluorescence microscopy and AFM studies directly confirmed the adhesion of the best binding phage displaying the peptide LGFREKE to amorphous and crystalline Ni<sub>3</sub>B particles. The best binding peptide sequence could play an important role for the development of a new synthesis route of Ni<sub>3</sub>B in the presence of phage displaying the peptide, or the synthetic peptide, respectively, which would represent a complete new approach. The synthesis of Ni<sub>3</sub>B in the presence of LGFREKE could result in mono-disperse and peptide capped nanoparticles with well-defined and uniform sizes and shapes exhibiting new catalytic and magnetic properties. Furthermore, the utilisation of M13 phage as template for the Ni<sub>3</sub>B mineralisation could potentially serve as a viable alternative to create tailor-made boride composite materials by a biologically driven nano-assembly synthesis and structuring for the generation of thermoelectric devices and field effect transistors.



**Figure 2 Evaluation of the binding strength of each of the 42 identified phage clones.** The relative binding affinity of the phage clones to amorphous (A) and crystalline (B)  $Ni_3B$  nanoparticles was determined by titer assays at pH 7. The assay was repeated three-times for each clone and the elucidated phage amounts were arithmetically averaged. As a control, M13KE wild-type (M13wt) phage without a random peptide insert were compared in the same manner as the phage clones. Strong binding phage clones ( $> 10^9$  pfu/ml) are indicated with an arrow. Clones identified on amorphous  $Ni_3B$  are designated with an A, clones identified on crystalline  $Ni_3B$  are designated with a C.

## Methods

### Phage and bacteria strains

Recombinant M13 phage from the Ph.D.-7 heptapeptide library (New England Biolabs, MA) were amplified and propagated in the *E. coli* host strain ER2738 ( $F'$ ,  $lacI^q$ ,  $\Delta(lacZ)M15$ ,  $proA^+B^+$   $zff::Tn10(Tet^R)/fhuA2$ ,  $supE$ ,  $thi-1$ ,  $\Delta(lac-proAB)$ ,  $\Delta(hsdS-mcrB)5$ ,  $[r_{k_m}^-McrBC^-]$ ), as described by the manufacturer. M13KE wild-type (M13wt) phage was used for the determination of unspecific binding to the  $Ni_3B$  targets. Bacteria cultures were maintained in lysogeny broth (LB) [41].

### Peptide library screening

$Ni_3B$ -binding peptides were identified using a commercially available M13 bacteriophage display library (Ph.D.-7;

New England Biolabs) with random 7-mer peptides. The DNA sequences of the 7-mer peptides are N-terminal fusions to the minor coat protein p3 of the bacteriophage M13. A short linker sequence (GGGS) separates each random peptide from the minor coat protein p3. The phage display library consists of approximately  $1.28 \times 10^9$  different peptides. The target binding, elution, and phage amplification steps were conducted according to the manufacturer's instructions. 20 mg of amorphous or crystalline  $Ni_3B$  nanoparticles were used as targets. The targets were washed three-times with Tris-buffered saline (TBS, 50 mM Tris-HCl, pH 7, and 150 mM NaCl) and blocked with TBS supplemented with 5 mg/ml of BSA for 1 hour. The blocked targets were then washed three-times with TBS. To each target, a total number of  $2 \times 10^{11}$  phage in

**Table 4 Strong binders identified by relative binding affinity experiments**

Ni <sub>3</sub> B amorphous target					
#	Peptide	Frequency	Phage titer (pfu/ml)	Sequence	pI
1	A7	1/30	6.1 × 10 <sup>9</sup>	LGFREKE	6.14
2	A3	4/30	4.6 × 10 <sup>9</sup>	SLAVSRS	9.47
3	A2	6/30	3.8 × 10 <sup>9</sup>	GALPNNL	5.52
4	C15	1/28	2.8 × 10 <sup>9</sup>	LEQTPMF	4.00
5	C13	1/28	2.4 × 10 <sup>9</sup>	GPVNHQL	6.74
6	C4	1/28	2.4 × 10 <sup>9</sup>	VPIPYLP	5.49
7	C24	1/28	1.9 × 10 <sup>9</sup>	SPSTHWK	8.49
8	C9	1/28	1.8 × 10 <sup>9</sup>	SASKVHN	8.49
9	A1	8/30	1.5 × 10 <sup>9</sup>	TNLTLAS	5.19
Ni <sub>3</sub> B crystalline target					
#	Peptide	Frequency	Phage titer (pfu/ml)	Sequence	pI
1	A7	1/30	5.1 × 10 <sup>9</sup>	LGFREKE	6.14
2	C12	1/28	2.1 × 10 <sup>9</sup>	YQVVPAR	8.75
3	C15	1/28	1.8 × 10 <sup>9</sup>	LEQTPMF	4.00

1 ml of TBS with 0.1% Tween-20 (0.1% TBST) were incubated for 1 hour. Non-specifically or weakly bound phage particles were removed by washing ten-times with 0.1% TBST. The remaining bound phage particles were eluted with a solution containing 0.2 M glycine-HCl, pH 2.2 and 1 mg/ml BSA. After centrifugation, the supernatant was removed from the target and neutralised with 1 M of Tris-HCl, pH 9. The eluted phage were amplified through infection into *E. coli* ER2738, followed by purification by precipitation with polyethylene glycol according to the manufacturer's instructions. This completed a round of panning. The entire biopanning process was repeated five rounds to enrich for tight binders. To inhibit the hydrophobic interactions between the phage library and the Ni<sub>3</sub>B targets, the concentration of Tween-20 was successively increased in each panning step from 0.1%, 0.3%, 0.5%, 0.6%, and 0.8%, respectively. After the fourth and fifth

**Table 5 Competitive binding assay results for amorphous Ni<sub>3</sub>B target**

Peptide	Sequence	Frequency
A7	LGFREKE	17/29
C24	SPSTHWK	3/29
C9	SASKVHN	2/29
C15	LEQTPMF	2/29
A1	TNLTLAS	1/29
A2	GALPNNL	1/29
C4	VPIPYLP	1/29
C13	GPVNHQL	1/29
A3	SLAVSRS	0/29

**Table 6 Competitive binding assay results for crystalline Ni<sub>3</sub>B target**

Peptide	Sequence	Frequency
A7	LGFREKE	13/29
C9	SASKVHN	5/29
C24	SPSTHWK	5/29
C13	GPVNHQL	4/29
C4	VPIPYLP	1/29
C15	LEQTPMF	1/29
A1	TNLTLAS	0/29
A2	GALPNNL	0/29
A3	SLAVSRS	0/29

round of screening, the eluted phage were diluted and titrated on LB agar plates containing 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (Xgal) and isopropyl-β-D-thiogalactopyranosid (IPTG). A total of 58 randomly selected phage plaques, which appeared blue, were picked and analysed by DNA sequencing. The phage titer was determined by titration according to manufacturer's recommendations using appropriate dilutions of the precipitated phage.


#### Binding affinity assays

The binding affinity of each identified phage clone with the Ni<sub>3</sub>B substrates was demonstrated by mixing equivalent phage amounts (1 × 10<sup>10</sup> pfu/ml) of individual phage clones with either 20 mg of amorphous or crystalline Ni<sub>3</sub>B nanoparticles in 1 ml of TBS containing 0.8% Tween-20. After 1 hour incubation at room temperature the unbound phage were removed by washing the substrates ten-times. Bound phage were then isolated using the standard acidic elution method as used in the screening procedure. For each clone, the bound phage amount was elucidated by titration according to manufacturer's recommendations using appropriate dilutions of the eluted phage. The binding strength of a single clone directly correlates with the phage titer of the eluted phage. The assay was repeated three-times for each clone and the elucidated phage titers were arithmetically averaged. M13KE wild-type phage, with no random peptides displayed on the p3 protein, was used as a control.

#### Competitive binding assays

The phages with the highest binding affinity to either amorphous or crystalline Ni<sub>3</sub>B were evaluated by the method of a competitive binding assay. For this assay, the individual phage clones of the nine strongest binders on amorphous Ni<sub>3</sub>B as determined by binding affinity assays, were separately amplified and diluted into a mini-phage library at a concentration of 1 × 10<sup>7</sup> pfu/μl per clone. Subsequently 1 × 10<sup>10</sup> pfu/ml of this minimised phage library was applied to amorphous or crystalline Ni<sub>3</sub>B nanoparticles






**Figure 3 Analysis of the phage binding by fluorescence microscopy.** Confocal fluorescence (A, C) and transmission optical microscopy (B, D) of LGFREKE phage bound to amorphous (A, B) and crystalline (C, D) Ni<sub>3</sub>B nanoparticles. The samples were dyed using a fluorescently tagged anti-M13 monoclonal antibody. Confocal fluorescence (E, G) and transmission optical microscopy (F, H) of the control experiments of amorphous and crystalline Ni<sub>3</sub>B nanoparticles, respectively, which were preincubated with M13KE wild-type (M13wt) phage before incubation with the fluorescently tagged antibody.

as described for the procedure of the binding affinity assays. After a single panning round, the weakly bound phages were removed by washing the substrates and the remaining strongly bound phages were isolated using the standard acidic elution method as used in the screening procedure. The eluted phages were quantified by titration according to the manufacturer's recommendations. The assay was repeated three-times for each substrate. A total number of 29 plaques were randomly picked for each substrate and sequenced to reveal the most strongly binding peptide sequences.

#### Synthesis and characterisation of amorphous and crystalline Ni<sub>3</sub>B

The Ni<sub>3</sub>B nanoparticles were synthesised from NaBH<sub>4</sub> (Alfa Aesar, 97%) and NiCl<sub>2</sub> × 6 H<sub>2</sub>O (Grüssing GmbH,



**Figure 4 Visualisation of the phage binding by atomic force microscopy.** Topographic AFM images of the binding of modified M13 phage (LGFREKE) to amorphous (A) and crystalline (B) Ni<sub>3</sub>B nanoparticles. The AFM images of M13 phage displaying the A7 peptide on p3 showed the phage to bind to several amorphous and crystalline Ni<sub>3</sub>B nanoparticles at the tip of p3, which are indicated by arrows. The colour scale exceeds the particle height to better display the particle cross section.

98%) in aqueous solution at about 0°C following a synthesis route described earlier [5]. According to this procedure amorphous Ni<sub>3</sub>B is formed primarily, which is transformed into the crystallised Ni<sub>3</sub>B sample at 490°C in vacuum ( $5 \times 10^{-3}$  mbar, 18 h). The X-ray diffraction pattern of the annealed, crystalline sample allows for its identification as Ni<sub>3</sub>B (see Additional file 1). In previous work, we have shown using methods like X-ray diffraction, energy-dispersive X-ray spectroscopy, X-ray absorption spectroscopy, scanning and transmission electron microscopy, and energy-loss electron spectroscopy that the corresponding amorphous phase actually consists of the same boride as

the crystalline modification [5,7]. For the phage display the amorphous Ni<sub>3</sub>B nanoparticles were used after extensive washing with deionized water and drying in a desiccator under vacuum. The crystalline nanoparticles were obtained from the amorphous product after the annealing process and used directly.

### Fluorescence microscopy analysis

The binding of M13 phage to amorphous and crystalline nickel boride nanoparticles was characterised with a Zeiss Axiovert 200 inverted fluorescence microscope equipped with a Zeiss AxioCam HRm. The fluorescence images were taken using emission at 528 nm. M13 phage were incubated with 10 mg of amorphous and crystalline Ni<sub>3</sub>B nanoparticles at a concentration of  $3 \times 10^{12}$  pfu/ml in 1 ml TBS supplemented with 0.8% Tween-20. After 2 h at room temperature, unbound phage were removed by washing the substrates three-times with TBS. Subsequently, the substrates were blocked with TBS supplemented with 2% BSA and 0.05% Tween-20 for 1 hour and washed three-times with TBS supplemented with 0.05% Tween-20. The samples were dyed using a FITC tagged anti-M13 monoclonal antibody against phage coat protein p8 (Acris Antibodies, Inc., Herford, Germany). Each target was incubated for 1 hour with 1 µg/ml of labeled monoclonal antibodies in TBS with 0.05% Tween-20. After removing unbound antibodies by washing the samples three-times with TBS containing 0.05% Tween-20, the samples were analysed by fluorescence microscopy.

### Atomic force microscopy (AFM) analysis

Ni<sub>3</sub>B nanoparticles, phages and compounds of phages with Ni<sub>3</sub>B were characterised with an atomic force microscope (AFM). The measurements were carried out on a Dimension Icon AFM with a Nanoscope V controller (Bruker, Santa Barbara, California) in ambient conditions. The measurements were performed in tapping mode, to minimise the lateral interaction. Silicon cantilevers (PPP NCH, Nanosensors) with a nominal resonance frequency of 330 kHz, spring constant of 42 Nm<sup>-1</sup>, and a nominal tip diameter of less than 10 nm were used. All images were taken at a resolution of 512 × 512 pixel<sup>2</sup>. M13 phages were incubated with 10 mg of amorphous and crystalline Ni<sub>3</sub>B nanoparticles at a concentration of  $3 \times 10^{12}$  pfu/ml in 1 ml TBS supplemented with 0.8% Tween-20. After 2 h, unbound phages were removed by washing the substrates three-times with TBS. Samples were prepared by dropping the sample suspension on a silicon wafer or freshly cleaved mica. The samples were dried in a stream of dry nitrogen. Image analysis and processing was performed with the Nanoscope Analysis software Version 1.40 (Bruker). A plane correction procedure and a line by line fit were used to compensate for the sample tilt.

## Additional file

**Additional file 1: X-ray powder diffraction profile.** Calculated (solid blue line) and difference (solid red line) X-ray powder diffraction profiles for the Rietveld refinement of crystalline Ni<sub>3</sub>B. Reflection positions are marked (blue bars).

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

SJF and MP drafted the manuscript. CB and KH synthesised the Ni<sub>3</sub>B substrates for the use in biopanning. MP identified and characterised the binding peptides, and visualised the adhesion of the phage by fluorescence microscopy. LZ did the AFM analysis of Ni<sub>3</sub>B nanoparticles, phages and compounds of phages with Ni<sub>3</sub>B. BA, SJF, RWS, and BH planned and designed this project. SJF, MP and BA read and approved the final manuscript. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) under grant HA 1251/2-1, STA 1026/5-1, and AL 536/11-1 as part of the Priority Programme SPP 1569 "Generation of multifunctional inorganic materials by molecular bionics".

### Author details

<sup>1</sup>Institute of Technical Biochemistry, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany. <sup>2</sup>Eduard-Zintl-Institute of Inorganic and Physical Chemistry, Technische Universität Darmstadt, Alarich-Weiss-Str. 12, 64287 Darmstadt, Germany. <sup>3</sup>Center of Smart Interfaces, Physics of Surfaces and Institute of Materials Sciences, Technische Universität Darmstadt, Alarich-Weiss-Str. 10, 64287 Darmstadt, Germany.

Received: 31 May 2013 Accepted: 29 January 2014

Published: 10 February 2014

### References

- Schwarzkopf P, Kieffer R: *Refractory Hard Metals*. 1st edition. The Macmillan Company: New York; 1953:311–312.
- Buzea C, Yamashita T: Review of the superconducting properties of MgB<sub>2</sub>. *Supercond Sci Technol* 2001, **14**:R115–R146.
- Herbst JF, Croat JJ: Neodymium-iron-boron permanent magnets. *J Magn Magn Mater* 1991, **100**:57–78.
- Brown HC, Brown CA: New, highly active metal catalysts for the hydrolysis of borohydride. *J Am Chem Soc* 1962, **84**:1493–1494.
- Kapfenberger C, Hofmann K, Albert A: Room-temperature synthesis of metal borides. *J Solid State Sci* 2003, **5**:925–930.
- Caputo R, Guzzetta F, Angerhofer A: Room-temperature synthesis of nickel borides via decomposition of NaBH<sub>4</sub> promoted by nickel bromide. *Inorg Chem* 2010, **49**:8756–8762.
- Rades S, Kornowski A, Weller H, Albert B: Wet-chemical synthesis of nanoscale iron boride. *Chem Phys Chem* 2011, **12**:1756–1760.
- Chen CL, Rosi NL: Peptide-based methods for the preparation of nanostructured inorganic materials. *Angew Chem Int Ed* 2010, **49**:1924–1942.
- Boar RB, Hawkins DW, McGhie JF, Barton DHR: Some applications of nickel boride as a desulphurising agent. An improved route to triterpene 2-enes. *J Chem Soc, Perkin Trans* 1973, **1**:654–657.
- Sarma DN, Sharma RP: Nickel boride reductive cleavage of allylic trimethylsilyl ethers. *Tetrahedr Lett* 1985, **26**:371–372.
- Seltzmann HH, Berrang BD: Nickel boride reduction of aryl nitro compounds. *Tetrahedr Lett* 1993, **34**:3083–3086.
- Molvinger K, Lopez M, Court J: Enantioselective borane reduction of ketones with oxazaborolidines boron-bound to nickel boride nanoparticles. *Tetrahedr Lett* 1999, **40**:8375–8378.
- Saxena I, Borah R, Sarma JC: Reductive amination of aromatic aldehydes and ketones with nickel boride. *J Chem Soc, Perkin Trans* 2000, **1**:503–504.
- Brown CA: Catalytic hydrogenation. V. The reaction of sodium borohydride with aqueous nickel salts. P-1 nickel boride, a convenient,

- highly active nickel hydrogenation catalyst. *J Org Chem* 1970, **35**:1900–1904.
15. Pavlik JW: Catalytic hydrogenation using nickel boride. *J Chem Educ* 1972, **49**:528.
  16. Bratkovsky AM, Rashkeev SN, Wendin G: Electronic structure, ferromagnetism, and EELS spectra of crystalline alloys Fe<sub>n</sub>B and Ni<sub>n</sub>B (n = 1, 2, 3): Aspects of universal behavior. *Phys Rev B* 1993, **48**:6260–6270.
  17. Schaefer ZL, Ke X, Schiffer P, Schaak RE: Direct solution synthesis, reaction pathway studies, and structural characterization of crystalline Ni<sub>3</sub>B nanoparticles. *J Phys Chem C* 2008, **112**:19846–19851.
  18. Sarikaya M, Tamerler C, Jen AKY, Schulten K, Baneyx F: Molecular biomimetics: nanotechnology through biology. *Nat Mater* 2003, **2**:577–585.
  19. Baneyx F, Schwartz DT: Selection and analysis of solid-binding peptides. *Curr Opin Biotechnol* 2007, **18**:312–317.
  20. Whyburn GP, Li Y, Huang Y: Protein and protein assembly based material structures. *J Mater Chem* 2008, **18**:3755–3762.
  21. Smith GP, Petrenko VA: Phage Display. *Chem Rev* 1997, **97**:391–410.
  22. Naik RR, Stringer SJ, Agarwal G, Jones SE, Stone MO: Biomimetic synthesis and patterning of silver nanoparticles. *Nat Mater* 2002, **1**:169–172.
  23. Heinz H, Farmer BL, Pandey RB, Slocik JM, Patnaik SS, Pachter R, Naik RR: Nature of molecular interactions of peptides with gold, palladium, and Pd-Au bimetal surfaces in aqueous solution. *J Am Chem Soc* 2009, **131**:9704–9714.
  24. Umetsu M, Mizuta M, Tsumoto K, Ohara S, Takami S, Watanabe H, Kumagai I, Adschiri T: Bioassisted room-temperature immobilization and mineralization of zinc oxide - The structural ordering of ZnO nanoparticles into a flower-type morphology. *Adv Mater* 2005, **17**:2571–2575.
  25. Rothenstein D, Claasen B, Omiecienski B, Lammel P, Bill J: Isolation of ZnO-binding 12-mer peptides and determination of their binding epitopes by NMR spectroscopy. *J Am Chem Soc* 2012, **134**:12547–12556.
  26. Naik RR, Brott LL, Claron SJ, Stone MO: Silica-precipitating peptides isolated from a combinatorial phage display peptide library. *J Nanosci Nanotechnol* 2002, **2**:95–100.
  27. Dickerson MB, Jones SE, Cai Y, Ahmad G, Naik RR, Kröger N, Sandhage KH: Identification and design of peptides for the rapid, high-yield formation of nanoparticulate TiO<sub>2</sub> from aqueous solutions at room temperature. *Chem Mater* 2008, **20**:1578–1584.
  28. Lee SW, Mao C, Flynn CE, Belcher AM: Ordering of quantum dots using genetically engineered viruses. *Science* 2002, **296**:892–895.
  29. Flynn CE, Mao CB, Hayhurst A, Williams JL, Georgiou G, Iverson B, Belcher AM: Synthesis and organization of nanoscale II-VI semiconductor materials using evolved peptide specificity and viral capsid assembly. *J Mater Chem* 2003, **13**:2414–2421.
  30. Dong J, Chuan L, Zhang J, Xin ZT, Yang G, Gao B, Mao CQ, Liu NL, Shao NS, Fan M, Xue YN: Selection of novel nickel-binding peptides from flagella displayed secondary peptide library. *Chem Biol Drug Des* 2006, **68**:107–112.
  31. Chung KCC, Cao L, Dias AV, Pickering IJ, George GN, Zamble DB: A high-affinity metal-binding peptide from *Escherichia coli* HypB. *J Am Chem Soc* 2008, **130**:14056–14057.
  32. Zoroddu MA, Medici S, Peana M: Copper and nickel binding in multi-histidinic peptide fragments. *J Inorg Biochem* 2009, **103**:1214–1220.
  33. Thomas CJ, Sharama S, Kumar G, Visweswariah SS, Suroliya A: Biopanning of endotoxin-specific phage displayed peptides. *Biochem Biophys Res Commun* 2003, **307**:133–138.
  34. Okamoto Y, Nitta Y, Imanaka T: Surface characterisation of nickel boride and nickel phosphide catalysts by X-ray photoelectron spectroscopy. *J Chem Soc, Faraday Trans* 1978, **1**:2027–2039.
  35. Jaworski JW, Raorane D, Huh JH, Majumdar A, Lee SW: Evolutionary screening of biomimetic coatings for selective detection of explosives. *Langmuir* 2008, **24**:4938–4943.
  36. Willett RL, Baldwin KW, West KW, Pfeiffer LN: Differential adhesion of amino acids to inorganic surfaces. *PNAS* 2005, **102**:7817–7822.
  37. Amaral M, Lopes MA, Santos JD, Silva RF: Wettability and surface charge of Si<sub>3</sub>N<sub>4</sub>-bioglass composites in contact with simulated physiological liquids. *Biomaterials* 2002, **23**:4123–4129.
  38. Fahrenholtz WG, Hilmas GE, Talmy IG, Zaykoski JA: Refractory diborides of zirconium and hafnium. *J Am Ceram Soc* 2007, **90**:1347–1364.
  39. Brown D, Ma B-M, Chen Z: Developments in the processing and properties of NdFeB-type permanent magnets. *J Magn Magn Mater* 2002, **248**:432–440.
  40. Nagamatsu J, Nakagawa N, Muranaka T, Zenitani Y, Akimitsu J: Superconductivity at 39 K in magnesium diboride. *Nature* 2001, **410**:63–64.
  41. Bertani G: Studies on lysogenesis. I. The mode of phage liberation by lysogenic *Escherichia coli*. *J Bacteriol* 1951, **62**:293–300.

doi:10.1186/1472-6750-14-12

Cite this article as: Ploss et al.: Selection of peptides binding to metallic borides by screening M13 phage display libraries. *BMC Biotechnology* 2014 **14**:12.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

